FindTrial
Sign In

CT scan administrated contrast agents effect on radiation dose calculation in treatment planning of radiotherapy

Assessment the influence of CT scan administrated contrast agents on radiation dose calculation in treatment planning of radiotherapy compared to the calculation based on non-enhanced CT scan in patients with cancer of the rectum, prostate and cervix

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015051922319N1
Enrollment
11
Registered
2015-06-03
Start date
2015-05-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Rectum cancer. Condition 2: Prostate cancer. Condition 3: Cervix cancer. Malignant neoplasm of rectum Malignant neoplasm of prostate Malignant neoplasm of cervix uteri

Interventions

Interventions 1: Meglumine compound 370mgI/ml as oral contrast and Iodixanol 320mgI/ml as intravenous contrast.
Diagnosis
Interventions 1: Meglumine compound 370mgI/ml as oral contrast and Iodixanol 320mgI/ml as intravenous contrast

Sponsors

Vice chancellor for research, Kermanshah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients referred to the Radiotherapy-Oncology ward because of the rectum, prostate and cervix cancers; Exclusion criteria: Renal diseases, Diabetes, Allergic asthma, Food and Drug allergies, Prior reactions to contrast agents and taking some drugs like Metformin

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Radiation dose. Timepoint: Before and after the intervention. Method of measurement: Dosimetry with treatment planning system.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSahel Heydarheydari

Kermanshah University of Medical Sciences

a.haghparast@kums.ac.ir; negin10860@yahoo.com; sheydari7@gmail.com+98 83 3729 0469

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026